Table 1.

Epigenetic Analysis of IGF2 in Serous Epithelial Ovarian Tumors

CharacteristicnAge (Avg)CTCF-1*CTCF-6*,IGF2 DMRLOI§
Borderline541.42/20/52/30/2
Early stage (I/II)955.26/21/84/50/2
Advanced stage (III/IV)6460.937/1628/2914/445/16
Normal lymphocytes
43
N/A
3/30
2/37
2/41
N/A
Age at diagnosis (y)
    ≤501744.910/55/117/101/3
    >505664.833/1324/2511/394/15
    Fisher's exact P


1.00
0.27
0.21
1.00
Survival (advanced stage)
    ≤3 y postdiagnosis3059.716/612/137/203/7
    ≥7 y postdiagnosis2460.115/611/116/152/7
    Fisher's exact P


1.00
1.00
1.00
1.00
IGF2 expression
    Microarray ≤902657.611/95/1710/144/3
    Microarray >903560.725/518/147/241/12
    Fisher's exact P


0.05
0.02
0.15
0.03
Epigenetic features
    Borderline vs malignant0.580.070.611.00
    Stage I/II vs III/IV1.000.070.241.00
    Malignant vs lymphocytes<0.0001<0.00010.004N/A
  • Abbreviation: N/A, not applicable.

  • * Number exhibiting hypermethylation/number exhibiting differential methylation.

  • One sample was not tabulated here because it was hypermethylated at CTCF-6.

  • Number exhibiting hypomethylation/number exhibiting differential methylation.

  • § Number with loss of IGF2 imprinting/number with maintenance of imprinting.

  • Normal lymphocytes were from individuals without evident malignancy.

  • Fisher's exact P.